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Background: The purpose of this study was to determine the effectiveness and safety of 
morphine sulfate extended-release capsules among primary care patients with chronic, moderate-
to-severe pain using a universal precautions approach that assessed and monitored risk for 
opioid misuse and abuse.
Methods: This open-label, uncontrolled, multicenter, prospective study was conducted in 
primary care centers (n = 281) and included opioid-naïve and opioid-experienced patients with 
either a pain score $4 (0 = no pain, 10 = pain as bad as you can imagine), or with unacceptable 
side effects while taking opioids. The patients were treated with morphine sulfate extended-
release capsules for up to four months. Patient-rated pain intensity (worst, least, average) over 
the past 24 hours (0–10 scale), pain interference with seven activities of daily living (0 = no 
interference, 10 = completely interferes), and adverse events were recorded.
Results: Of 1487 patients who filled at least one prescription, 561 (38%) completed the study. 
Patients were primarily white (87%) and female (57%); 92% had pain for more than one year; 
and 79% were opioid-experienced. Median age was 52 years. Decreases in mean (± standard 
deviation) average pain scores (baseline 6.2 ± 2.3) were −0.8 ± 2.2 at visit 2 (5–14 days later), 
and −1.6 ± 2.3 and −1.7 ± 2.2 at visits 3 and 4 (spaced 3–4 weeks apart), respectively, and 
−1.1 ± 2.4 at visit 5 (included patients withdrawn from the study who were no longer taking 
the study drug). A similar trend was observed for worst pain and least pain scores and for pain 
interference with activities. Fifty-one percent of the safety population patients and 81% in the 
completer population reported being satisfied or very satisfied with the study treatment. Most 
common adverse events were typical of opioids, ie, constipation (14%), nausea (11%), vomiting 
(5%), and somnolence (5%).
Conclusion: The results suggest that pain outcomes improved in patients with chronic, 
  moderate-to-severe pain receiving morphine sulfate extended-release capsules within the context 
of a structured universal precautions approach in the primary care setting.
Keywords: opioids, analgesics, primary care, pain assessment, substance abuse, universal 
precautions
Introduction
One of the challenges associated with using opioid therapy for pain management 
is achieving benefit in an environment in which the misuse, abuse, and diversion 
of prescription pain medications have become nearly as common as use of illicit 
drugs.1–3 Before therapy is initiated, all patients under consideration for management Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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with opioids should receive a thorough diagnostic workup 
and evaluation, and careful assessment of risk for opioid 
abuse.4,5 Treatment goals should be established   during 
patient-  physician discussions.4 Guidelines recommend 
stratification of patients according to potential risk of aberrant 
behavior to aid in the choice of appropriate management 
and intervention.4,6 Gourlay et al have suggested using a 
“universal precautions” approach, modeled after that for 
infectious disease, whereby an appropriate minimum level 
of precaution is applied to all patients.6 Such an approach 
for pain management assumes all patients considered for 
opioid therapy should be screened for potential opioid or 
other drug misuse/abuse. Once opioid therapy has been 
initiated, all patients should be carefully monitored, with 
interventions based on their underlying risk factors and any 
emergent issues.4,6
Primary care providers are the largest single group of 
opioid prescribers in the United States.7 In general, primary 
care providers are the first to see patients with acute and 
chronic pain.8,9 However, there are few published studies on 
opioid misuse and abuse among patients on long-term opioid 
therapy for the management of chronic, moderate-to-severe 
pain in a primary care setting.10,11 Providers who have little 
specific training in pain medicine or addiction may be faced 
with providing pain management while managing the risks 
of misuse, abuse, and diversion associated with opioid 
analgesics.8,9,12,13
There are no large-scale studies to date assessing the 
effectiveness of opioids in pain management (eg, control of 
pain and/or improvement of function at tolerable doses) while 
employing a universal precautions approach in the primary 
care setting. The current multicenter, uncontrolled, open-
label study,14 conducted in the primary care setting among a 
broad geographically distributed population, evaluated the 
effectiveness and tolerability of morphine sulfate extended-
release capsules (Avinza®, King Pharmaceuticals Inc, Bristol, 
TN, acquired by Pfizer Inc in March 2011) in patients 
with chronic, moderate-to-severe pain.15 Effectiveness, an 
evaluation of treatment under real-world conditions,16,17 was 
based on pain and functional assessments. This study was 
also designed to assess risk of opioid misuse and abuse, and 
the utility of a universal precautions approach in the primary 
care setting.
The universal precautions approach in this study included 
evaluation, documentation, and monitoring for potential risk 
of opioid misuse and abuse during treatment, intervention 
when aberrant drug-related behaviors were identified, and 
regular assessments to ensure that pain management goals 
were being met.6 Morphine sulfate extended-release, which 
contains both immediate-release and extended-release beads 
of morphine sulfate, is intended for once-daily administration 
for the relief of moderate-to-severe pain requiring around-
the-clock opioid therapy for an extended period of time.15
The primary study objectives were to evaluate the 
effectiveness and safety of morphine sulfate extended-
release in a primary care setting, assess the potential risk 
of misuse and abuse, and monitor aberrant behaviors 
and interventions among patients receiving the study 
drug. Secondary objectives were to determine the level 
of compliance using a universal precautions approach to 
chronic pain management during the study and after study 
completion, and to evaluate the activities of daily living of 
patients on chronic opioid therapy with morphine sulfate 
extended-release.
This paper focuses on the effectiveness and safety of 
morphine sulfate extended-release and the impact of chronic 
pain management on activities of daily living when pain was 
managed using a universal precautions approach to assess 
and monitor pain and risk of opioid abuse; a separate paper 
will report the results for risk of misuse and abuse and level 
of compliance in this study.
Methods
Before study initiation, the protocol and informed consent 
form were approved by an independent central institutional 
review board. All patients provided signed informed 
consent before beginning screening/baseline procedures. 
The investigator was responsible for ensuring that the study 
was conducted in accordance with the protocol, current 
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use Guidelines on Good Clinical Practice, and regulatory 
requirements. Study centers were selected from a nationally 
representative list of primary care physicians with experience 
in prescribing opioids. Investigators were questioned 
about their ability to complete the study requirements, and 
their credentials with respect to the Drug Enforcement 
Administration were verified. Investigators involved in the 
study participated in a 1.5-hour training program conducted 
live or via Webcast that reviewed procedures to be used and 
counseling to be provided to the patients. Those investigators 
who completed the training also received an hour-long 
instructional DVD on study procedures that they could review 
as needed during the study.Journal of Pain Research 2011:4
Screening/baseline
(visit 1)
Screened n = 1612
Enrolled n = 1570
Safety population
(treated)
n = 1487
Treatment
(visit 2)
5–14 days after visit 1
End of study
(visit 5)
23–30 days after visit 4
patient completed study.
Completer population n = 561
Total n = 1118
Treatment
(visit 4)
23–30 days after visit 3
Treatment
(visit 3)
23–30 days after
visit 2 or visit 2A
Treatment
(visit 2A)
5–14 days after visit 2
if a stable dose was
not achieved
Stable dose achieved
Patient withdrawal
n = 890
Reasons for withdrawal
Patient choice
Adverse event
Other
Treatment failure
Lost to follow-up*
Investigator discretion
High risk for misuse/abuse
Noncompliance
Death
Illegal action with study drug
n = 472
n = 306
n = 157
n = 106
n = 89
n = 64
n = 47
n = 41
n = 9
n = 4
Stable dose NOT achieved
Figure 1 study design.
Notes: *One patient categorized as “lost to follow-up” upon study termination was later identified as having died due to renal failure. 
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Patients
Patients were adults (aged $ 21 years) who had chronic, 
moderate-to-severe pain for at least three months prior to 
study entry. They could be opioid-naïve with a pain score $ 4 
on an 11-point numerical rating scale (0 = no pain, 10 = pain 
as bad as you can imagine) or opioid-experienced but with 
suboptimal response (numerical rating scale pain score $ 4 or 
unacceptable side effects). Patients were required to be able 
to read and understand English and comply with protocol 
requirements.
Main exclusion criteria were hypersensitivity to mor-
phine, morphine salts, or any components of morphine sulfate 
extended-release, respiratory depression, acute or severe 
bronchial asthma or severe chronic obstructive pulmonary 
disease, currently taking morphine sulfate extended-release 
or would have required a dose of .1600 mg/day, pregnancy 
or breast-feeding, residing in a hospital or nursing home, or 
life expectancy less than two months. Patients could not 
have had more than two surgeries for lower back pain, or be 
required to undergo surgery or steroid injections for chronic 
pain over the next 12 weeks.
study design
This was an open-label, nonrandomized, uncontrolled, 
multicenter study that included three periods, ie, screening/
baseline, treatment, and end of study (Figure 1). During each 
visit, patients underwent a series of evaluations to assess the 
effectiveness and safety of morphine sulfate extended-release Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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and compliance under the universal precautions approach, 
to identify aberrant drug use, and to determine level of 
risk for misuse and abuse. At end of study and post-study, 
investigators completed assessments to determine their 
use of risk assessment tools and the universal precautions 
approach to pain management. Pain-related assessments 
will be discussed here; assessments of drug behavior and 
risk for misuse and abuse will be described in more detail 
in a separate paper.
Treatment with morphine sulfate extended-release was 
initiated without a washout period from prior medication. The 
initial morphine sulfate extended-release dose was tailored 
to the patient (per morphine sulfate extended-release con-
version tables and investigator discretion).15 In general, the 
starting dose was to be 30 mg once daily for opioid-naïve 
patients. Opioid-experienced patients were to be initiated on 
an equivalent daily dose of morphine sulfate extended-release 
given once daily and instructed to destroy any remaining prior 
medication. The investigator was allowed to adjust the dose 
throughout the study to achieve a stable dose, defined as a 
dose that provided a pain score ,4 on the numerical rating 
scale, required up to two doses of rescue medication daily, 
and provided a level of side effects deemed acceptable by 
patients and investigators. Determination of a stable dose 
was made at the discretion of the investigator. Patients were 
provided with a debit card for prescription medication to 
present to a pharmacy to receive study drugs free of charge. 
The card also allowed the investigator to obtain information 
about the date and location where the prescription was filled 
and the number of pills dispensed. The prescription card was 
reinitialized at visits 2 to 4.
Ibuprofen 200 mg (not to exceed 1200 mg/day unless 
directed by the prescriber) or acetaminophen 500 mg (not 
to exceed 4 g/day) could be taken as rescue medication; 
aspirin #325 mg/day was permitted for cardiovascular 
  prophylaxis; other analgesic medications were not   permitted. 
Concurrent nonanalgesic medications were permitted unless 
they were contraindicated for use with morphine sulfate 
extended-release, ibuprofen, or acetaminophen. Investigators 
were to take appropriate steps to prevent or minimize 
  constipation, including recommending the use of laxatives 
or stool softeners.
Outcome measures
Pain outcomes were measured using a patient-completed 
questionnaire that included components of the Brief Pain 
Inventory (Short Form).18 Questions included indication of 
any problems experienced since last visit; quantity of daily 
rescue medication required on average during the previous 
week (0 to .6 doses); rating of pain intensity (worst, least, 
and average) over the previous 24 hours, measured using an 
11-point numerical rating scale to rate pain intensity from 0 
(no pain) to 10 (pain as bad as you can imagine); how much 
pain relief had been achieved over the previous 24 hours from 
pain treatment or medications in 10% increments, from 0% 
(no relief) to 100% (complete relief); an indication (yes or 
no) whether the pain relief obtained from the current medica-
tion was enough to make a difference; and an assessment of 
how much pain had interfered with seven activities of daily 
living (general activity, mood, walking ability, normal work, 
relationships with other people, sleep, and enjoyment of life) 
during the previous 24 hours using an 11-point numerical 
rating scale from 0 (does not interfere) to 10 (completely 
interferes). The scores assessed at visits 2–5 were used to 
guide investigator decisions about patient pain management 
at each visit.
At baseline, the investigator determined each patient’s 
level of risk for misuse and abuse using scores obtained 
from the Screener and Opioid Assessment for Patients with 
  Pain-Revised (SOAPP®-R) questionnaire.19 Risk levels were 
then further adjusted by increasing the level if aberrant results 
were detected on urine drug screening and/or   aberrant drug 
behaviors were observed, including purposeful oversedation, 
frequent requests for early prescription renewals, increased 
dose without authorization, reports of lost or stolen 
prescriptions, or abuse of alcohol or illicit drugs. Patients 
considered to be at low risk for opioid misuse and abuse 
were treated with morphine sulfate extended-release and 
monitored; those at moderate risk were treated, provided 
with additional counseling and reminders of their treatment 
agreements and responsibilities, and monitored; and those 
considered at high risk were to be withdrawn from the 
study and potentially referred to a pain specialist and/or 
addictionologist.
At visit 5, ie, the end-of-study visit, all patients, including 
those who withdrew from the study, returned to the clinic 
for a final evaluation of pain and activity level, adverse 
events, and signs of aberrant behavior using the universal 
precautions approach. Patients who withdrew completed 
this visit at the time of withdrawal if they were at the study 
center at the time of withdrawal; if they withdrew between 
visits, they returned to the study center to complete this visit. 
Patients and investigators evaluated therapeutic response 
satisfaction with treatment using patient-completed Patient 
Global Assessment and investigator-completed Clinician 
Global Assessment tools for each patient. The Patient Global Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Assessment allowed the patient to compare morphine sulfate 
extended-release with his or her usual pain medication in 
the following four areas: pain relief during the whole day, 
ability to perform daily activities, ability to sleep, and side 
effects using a five-point rating scale (much better, better, 
same, worse, much worse); and to rate their satisfaction with 
the medication and investigator use of universal precautions 
tools employed in the study using a five-point rating scale 
(very satisfied, satisfied, neutral, dissatisfied, very dissatis-
fied). Investigators used a five-point scale on the Clinician 
Global Assessment tool to rate their satisfaction with study 
medication, level of improvement, and level of utility of 
the universal precautions intervention regimen (very satis-
fied, satisfied, neutral, dissatisfied, very dissatisfied). Safety 
assessments included vital signs, physical examination, and 
adverse events, which were categorized according to the 
Medical Dictionary for Regulatory Activities.
Analysis populations and withdrawal  
from study
For this study, the safety population included all patients 
who enrolled and filled a prescription for morphine sulfate 
extended-release. The intent-to-treat population included all 
patients with at least one completed visit in the treatment 
part of the study. The completer population included 
those patients who completed all treatment visits.
Patients could be withdrawn from the study at any time 
for reasons including, but not limited to: pregnancy, patient 
choice, investigator discretion (eg, occurrence of a serious 
adverse event, changes in patient condition that rendered 
study participation unacceptable), sponsor termination 
(eg, noncompliance, administrative reasons), assignment 
to high-risk level for misuse/abuse of prohibited drugs, or 
illegal activity involving morphine sulfate extended-release. 
Patients who had withdrawn from the study were asked to 
provide a reason for discontinuation, which was recorded by 
the investigator; more than one reason could be given.
statistical analysis
In this exploratory study, a sample size of 2000 patients 
from up to 600 centers was planned to provide 90% power 
to detect a change from baseline that was at least 7% of the 
standard deviation (SD) of the change score (one-sample 
t-test, significance level of 5%, two-sided). Due to later time 
constraints, 1612 patients were screened.
Analyses were based on all available data for the safety 
and completer populations. The investigator was to record 
all patient data and provide a documented explanation for 
any missing data. Descriptive statistics were used to report 
continuous variables, categorical variables, between subgroup 
comparisons, and changes from baseline. A paired t-test was 
used to compare changes from baseline in average pain scores 
in the last 24 hours at each visit and changes from baseline in 
pain relief at each visit. The primary outcome was the change 
from baseline in average pain score at each study visit. Second-
ary outcomes included change from baseline in the other pain 
scores, as well as change in pain interference with activities of 
daily living. Analyses were based on all available data at a time 
point. No imputation methods were employed. No multiple 
comparison adjustments were made for this exploratory study. 
Summaries of all available data were presented.
Results
Disposition, demographics, and baseline 
scores
A total of 286 primary care centers entered into the study and 
281 (with 281 investigators) contributed data. The investigators 
were from 34 states in the United States and from Puerto Rico. 
Of 1612 patients screened, 1570 (97%) were enrolled, 1487 
(92%) were enrolled and used the prescription card at least 
once (safety population), and 561 (561/1487; 38%) completed 
the study. There were 890 patients who withdrew during the 
course of the study and for whom a reason was recorded; the 
most common reasons for discontinuation (more than one 
could be provided) among these patients were patient choice 
(53%), adverse events (34%), and treatment failure (12%). 
Most patients who discontinued due to patient choice also 
had other reasons identified, most commonly adverse events 
(28%), treatment failure (16%), and investigator’s decision 
(4%). Patients rated as having a high risk level of misuse 
and abuse were required to be withdrawn from the study and 
accounted for 5% of discontinuations.
Results are reported based on all nonmissing data. 
Demographics and baseline characteristics of the safety 
population are shown in Table 1. The safety population was 
primarily female (57%), white (87%), and had chronic pain 
for more than one year (92%). Median age was 52 years 
(range 21–92 years). At baseline, 79% of patients were taking 
an opioid. The most common pain category, reported by 70% 
of patients, was musculoskeletal. The most common location 
of pain was the back (73%). Few patients indicated that they 
had a history of illicit drug use (5%) or had participated in 
a 12-step drug treatment program (2%). At baseline, mean 
(±SD) pain intensity scores were 6.2 ± 2.3 for average pain in 
the last 24 hours, 7.8 ± 2.5 for worst pain in the last 24 hours, 
and 4.7 ± 2.7 for least pain in the last 24 hours.Journal of Pain Research 2011:4
Table 1 Demographics and baseline characteristics
Characteristic Safety population 
n = 1487
n
Age (years) 
  Mean (sD) 
  Median 
  Range (minimum–maximum)
1470  
52.7 (13.62) 
52.0 
21–92
gender, n (%) 
  Men 
  Women
1469  
630 (43) 
839 (57)
Race, n (%) 
  White 
  Black 
  hispanic 
  Asian 
  Other
1434  
1240 (87) 
124 (9) 
55 (4) 
4 (0.3) 
11 (1)
Duration of current pain, n (%) 
  3–12 months 
  .1 year
1458  
120 (8) 
1338 (92)
Pain category,a n (%) 
  Musculoskeletal 
  Osteoarthritis 
  nerve-related 
  cancer-related 
  Other
 
1437 
1436 
1437 
1436 
1436
 
999 (70) 
349 (24) 
330 (23) 
12 (0.8) 
154 (11)
Pain location,a n (%) 
  Back 
  Limbs 
  Face/head/neck 
  Torso 
  Other
 
1467 
1467 
1466 
1466 
1466
 
1076 (73) 
632 (43) 
245 (17) 
117 (8) 
201 (14)
Pain score, mean (sD) 
  Average pain 
  Worst pain 
  Least pain
 
1474 
1475 
1475
 
6.2 (2.3) 
7.8 (2.5) 
4.7 (2.7)
concurrent medical conditions, n (%) 
  Depression 
  Anxiety/panic disorder 
  Diabetes mellitus 
  chronic constipation 
  history of cancer 
  Benign prostatic hypertrophy 
  nausea 
  Other
 
1480 
1480 
1480 
1480 
1480 
1480 
1480 
1480
 
622 (42) 
436 (30) 
287 (19) 
148 (10) 
79 (5) 
44 (3) 
30 (2) 
624 (42)
Participation in 12-step drug  
  treatment program, n (%)
1480 31 (2)
illicit drug use, n (%) 1444 72 (5)
Opioid experience (short-acting  
  and/or long-acting), n (%)
1481 1173 (79)
Note: aPatient could choose more than one category for etiology, location. 
Abbreviation: sD, standard deviation.
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effectiveness of morphine sulfate 
extended-release
Figure 2 shows the daily doses of morphine sulfate extended-
release prescribed at each of the study visits. Total daily doses 
ranged from 30 to 1440 mg. During visits 1–4 most ($83%) 
patients received a total daily dose of 30–120 mg; #17% 
patients received a total daily dose of $150 mg and #8% 
received a total daily dose of $240 mg.
Pain intensity scores were reduced from the baseline 
value at each visit (P , 0.0001 for all visits). In the safety 
population, the mean (±SD) change from baseline in average 
pain intensity in the last 24 hours (baseline 6.2 ± 2.3) at 
each visit was: visit 2 (−0.8 ± 2.2), visit 3 (−1.6 ± 2.3), and 
visit 4 (−1.7 ± 2.2, Figure 3A). At visit 5, which included 
scores from patients who had discontinued from the study 
as well as completed patients, the change from baseline was 
−1.1 ± 2.4. Similar trends were observed for pain at its worst 
and least in the last 24 hours at each visit. When patients were 
asked to report percent pain relief, mean values ranged from 
46.1% to 55.4% at each visit (P , 0.0001 at visits 3 and 4; 
not significant at visit 2 and at visit 5, which included those 
patients who had discontinued).
Patients experienced reductions in interference with 
activities of daily living scores, particularly in the   general 
activity, normal work, sleep, enjoyment of life, and 
walking ability categories; smaller effects were seen in mood 
and relationships with other people (Figure 4A and B). In 
response to the question “Is the amount of pain relief you 
are now obtaining from your current pain reliever (morphine 
sulfate extended-release) enough to make a difference?”, 
increasing percentages of the safety population between 
visits 2 and 4 (51.2% at visit 2, 77.3% at visit 3, and 79.4% 
at visit 4) replied in the affirmative.
Average daily use of rescue medication was 1–4 pills 
for most (60%–70%) patients at each visit. The percentage 
of patients using more than six pills ranged from 7.3% to 
10.5% across visits. The percentage of patients who had 
taken acetaminophen ranged from 40% to 47%. Percent use 
of ibuprofen ranged from 37% to 42%.
Effectiveness data were also evaluated for patients in 
the completer population. In this population, scores for 
mean (±SD) pain intensity on average also decreased from 
baseline (average pain in the last 24 hours 6.1 ± 1.7) at each 
subsequent visit, but the mean decrease from baseline in 
scores for average pain intensity in the last 24 hours was 
maintained through visit 5 and not increased from visit 4, as 
in the safety population (Figure 3B). Mean (±SD) decreases 
from baseline in average pain intensity scores in the last 
24 hours in the completer population were −0.9 ± 2.1 at visit 
2, −1.7 ± 2.2 at visit 3, −1.8 ± 2.2 at visit 4, and −1.7 ± 2.3 
at visit 5. Similar trends were observed for pain at its worst 
and least in the last 24 hours at each visit after baseline in 
the completer population (Figure 3B). For the completer Journal of Pain Research 2011:4
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n = 1476
2
n = 1050
3
n = 740
Visit number*
Safety population Daily dose (mg)
4
n = 612
0.5 1.6
4.5
6.2
9.6
20.9
56.6
21.8
39.9
17.4
9.0 8.3
2.8
14.5
26.6
25.8
17.6
10.3
3.6
1.6
12.9
24.8 25.0
19.9
12.1
3.6
1.6 0.8
10
0
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30
P
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t
i
e
n
t
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(
%
)
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60
90
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150–240
270–480
>500
Figure 2 Daily doses of morphine sulfate extended-release across study visits in safety population.
Note: *Values for n based on available data.
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population, mean patient-reported percent relief ranged from 
47% to 57%. Reductions in pain interference with activities 
of daily living were observed for all functions examined in 
the completer population (Figure 4B).
global assessments at visit 5
In-clinic Patient Global Assessment values at visit 5 are 
shown in Table 2. Of patients in the safety population, 89% 
indicated that they were satisfied or very satisfied with the 
investigator’s use of universal precautions tools (8%, neutral; 
2%, dissatisfied or very dissatisfied), and 51% indicated they 
were satisfied or very satisfied with their morphine sulfate 
extended-release treatment (18%, neutral; 30%, dissatisfied 
or very dissatisfied). Pain relief during the whole day was 
rated as better or much better by 56% (23%, same; 21%, 
worse or much worse); ability to perform daily activities by 
45% (31%, same; 24%, worse or much worse); sleep by 40% 
(40%, same; 20%, worse or much worse); and side effects by 
30% of patients in the safety population (29%, same; 41%, 
worse or much worse).
Of the completer population, 95% indicated they were 
satisfied or very satisfied with the investigator’s use of 
  universal precautions tools (5%, neutral; ,1% dissatisfied 
or very dissatisfied), and 81% indicated they were satisfied 
or very satisfied with their morphine sulfate extended-release 
treatment (14%, neutral; 5%, dissatisfied or very dissatisfied, 
Table 2). Pain relief during the whole day was rated as better 
or much better by 78% (15%, same; 6%, worse or much 
worse); ability to perform daily activities by 68% (26%, 
neutral; 7%, worse or much worse); sleep by 52% (40%, 
same; 8%, worse or much worse); and side effects by 51% 
of patients (35%, same; 14%, worse or much worse) in the 
completer population.
Using the Clinician Global Assessment, investigators 
reported being satisfied or very satisfied with the use of 
morphine sulfate extended-release for management of 
moderate-to-severe pain in 63% of patients in the safety 
population (19%, neutral; 18%, dissatisfied or very 
dissatisfied) and were satisfied or very satisfied with the 
level of improvement in chronic pain control in 63% of 
patients in the safety population (18%, neutral; 19%, 
dissatisfied or very dissatisfied, Table 3). In addition, 
investigators were satisfied or very satisfied with the utility 
of the universal precautions program in 75% of patients 
(21%, neutral; 4%, dissatisfied or very dissatisfied) in the 
safety population.
Investigators reported being satisfied or very satisfied 
with morphine sulfate extended-release use for management 
of moderate-to-severe pain in 91% of completed patients (6%, 
neutral; 3%, dissatisfied or very dissatisfied). Investigators 
were also satisfied or very satisfied with the improvement 
of chronic pain control in 90% of completed patients (7%, 
neutral; 3%, dissatisfied or very dissatisfied) and with the 
utility of the universal precautions program for 87% of the Journal of Pain Research 2011:4
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Figure 3 Pain intensity scores in the last 24 hours by study visit in the safety   
(A) and completer (B) populations.
Notes: *includes all patients including those who had discontinued from the study 
and were no longer taking study medication; †values for n based on available data. 
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completed patients (12%, neutral; 1%, dissatisfied or very 
dissatisfied, Table 3).
safety
Nearly half (48%) of the patients in the safety population 
experienced at least one adverse event. The most common 
adverse events reported were constipation (14%), nausea 
(11%), vomiting (5%), and somnolence (5%, see Table 4). 
Adverse events were identified as one reason for withdrawal 
from the study in 21% of the safety population; an 
additional 7% of patients reported adverse events leading to 
withdrawal of study medication on the adverse event case 
report forms. The most common adverse events ($1%) 
resulting in withdrawal from the study were nausea (8%; 
n = 114), constipation (5%; n = 77), vomiting (4%; n = 53), 
somnolence (3%; n = 40), fatigue (2%; n = 35), headache 
(2%; n = 32), dizziness (2%; n = 31), pruritus (2%; n = 26), 
and abdominal pain (1%; n = 18). Sixty patients (4%) in 
the safety population reported serious treatment-emergent 
adverse events, two of which (nausea) were considered 
treatment-related. The most common serious adverse events 
were pneumonia (n = 8), congestive cardiac failure (n = 4), 
gastrointestinal hemorrhage (n = 4), nausea (n = 4), hypo-
glycemia (n = 4), and acute renal failure (n = 5).
Ten deaths (0.7%) occurred during the study. Most 
were due to concomitant medical conditions and none were 
considered by the investigators to be attributable to the 
study drug. One death occurred in a 46-year-old man with 
significant diabetes and hypertension whose concomitant 
medications included metformin, glipizide, citalopram, and 
diazepam. At enrollment this patient indicated hydrocodone, 
nonsteroidal anti-inflammatory drugs, and tramadol as 
concurrent medications. The patient did not have a history 
of opioid abuse or recreational drug use. The starting dose 
of morphine sulfate extended-release was 240 mg/day. The 
coroner ruled that the death, which occurred five days after 
enrollment, was accidental secondary to the use of opiate, 
citalopram, and diazepam. In the investigator’s opinion, 
the death was not reasonably attributed to the study drug; 
however, the death was judged by the sponsor as reasonably 
attributable to the study drug.
Universal precautions
Most patients in the safety population (52%) were identified as 
being at moderate risk for opioid misuse and abuse at baseline, 
while 47% were assigned a low risk level, and 1% were 
assigned a high-risk level. On urine drug screen at baseline, 
14% of patients were reported as positive for marijuana and 
10% were reported as positive for cocaine. Positive urine drug 
screen results were also reported for other illicit drugs, such 
as phencyclidine and 3,4-methylenedioxymethamphetamine, 
each in 6% of patients. Positive urine drug screen results for 
illicit drugs were reported throughout all study visits. More 
detail regarding risks and incidence of misuse and abuse and 
levels of compliance will be reported in a separate paper.20
Discussion
In this population of primary care patients with chronic, 
moderate-to-severe pain, in a study assessing a universal 
precautions approach to determine risk level for opioid 
misuse and abuse and provide appropriate management, 
patients receiving morphine sulfate extended-release experi-
enced measurable improvement in pain control as measured Journal of Pain Research 2011:4
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by reduced pain intensity scores in both the safety and 
  completer populations. Pain scores fell until visit 3 when the 
dose of morphine sulfate extended-release was stabilized. 
Patients in both the safety and completer populations also 
experienced reduced interference of pain in activities of daily 
living, in all functions and activities evaluated. Fifty-one 
percent of patients in the safety population and 81% in the 
completer population reported being satisfied or very satisfied 
with morphine sulfate extended-release treatment.
In the current study, a statistical improvement in pain 
scores was observed. However, it did not reach the two-point 
criteria for a clinically important difference based on analyses 
of other studies in patients with various types of chronic 
pain21,22 or other studies using the same morphine sulfate 
extended-release formulation and a similar pain intensity 
scale.23,24 This is likely due to differences in methodology. 
In the current study, patients entered the trial on their pain 
medications without washout from previous analgesics 
and were not titrated to a prespecified pain intensity level 
before effectiveness was evaluated. They could also have 
been experiencing adequate relief but unsatisfactory side 
effects at baseline, thus limiting the potential reduction in 
pain scores. It was noted that patient-reported percent pain 
relief was numerically higher than that calculated based 
on decrease in pain intensity scores (46.1% to 55.4% pain 
relief reported by patients versus 27% calculated using pain 
intensity scores). The reason(s) for this difference is (are) 
unclear, but may include differences in patient interpreta-
tion of the scales, overestimation of pain scores, or inclusion 
of other considerations, such as quality of life or physical 
function, in assessing percent relief. Importantly, 81% of 
patients who completed the study reported being satisfied 
or very satisfied with treatment (as did 51% of all patients, 
including noncompleters), and by visits 3 and 4, 77% and 
79% of patients, respectively, reported that pain relief was 
enough to make a difference. Results suggest that assessment Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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of treatment success in future trials and in the clinical setting 
should include a focus on functional improvement.
The withdrawal rate in this study was 62%; the most com-
mon reasons (more than one could be provided) were patient 
choice, adverse events, and treatment failure. The overall rates 
appear toward the higher range of discontinuation rates of 
38%–63% observed in other studies using opioid therapy over 
a 2–6-month period for management of chronic, moderate-
to-severe pain,16,23,25–28 possibly due to the amount and types 
of monitoring required of patients. The discontinuation rates 
due to adverse events and treatment failure were similar to 
those reported in other studies.16,23,25–28 Unlike other studies, 
this study required that patients identified at high risk for 
opioid abuse be withdrawn. Although a small percentage 
(5%), this did contribute to the withdrawal rate observed. 
Other possible explanations for the high rate of withdrawal 
from the study included enrollment of sites that had not 
previously participated in a research study, patients with 
fear of exposure about misuse/abuse of illicit/nonprescribed 
drugs or who did not wish to be monitored for aberrant drug 
behavior, or patients who felt worse on morphine sulfate 
extended-release than while not taking the medication. While 
most patients reported being satisfied with investigator use 
of the universal precautions tools, it is possible that because 
this assessment was conducted during clinic visits, patients 
may not have been fully candid during their assessments. 
Nonetheless, the withdrawal rate observed in this study 
did not appear to affect assessments of the effectiveness of 
morphine sulfate extended-release because statistically sig-
nificant improvements on pain intensity scores were seen in 
both the safety population as well as the completers.
As with any open-label study, the design of the study 
limits generalization of the conclusions. It was not pos-
sible to exclude bias. Further, although the intention was to 
  provide a broad sampling of patients and investigators across 
the United States, patient demographics and investigator 
selection may not be representative of a “real-world” popula-
tion. The recruitment of investigators who had experience in 
prescribing opioids may have yielded a higher proportion of 
patients who had previously used opioids.
Study entry criteria were based on the presence of chronic, 
moderate-to-severe pain. Most patients were reported to have 
Table 2 Patient global assessment at visit 5
n (%) Safety population 
n = 1487
Completer population 
n = 561
Much better Better Much better Better
Pain relief during the whole day (24 hours), 
  safety n = 1113; completer n = 556
260 (23) 358 (32) 193 (35) 241 (43)
Ability to perform daily activities, 
  safety n = 1110; completer n = 555
174 (16) 325 (29) 139 (25) 236 (43)
Ability to sleep, 
  safety n = 1110; completer n = 556
154 (14) 292 (26) 98 (18) 191 (34)
side effects 
  safety n = 1085, completer n = 537
138 (13) 189 (17) 118 (22) 155 (29)
Very satisfied Satisfied Very satisfied Satisfied
satisfaction with morphine sulfate extended-release, 
  safety n = 1119; completer n = 557
299 (27) 275 (25) 252 (45) 197 (35)
satisfaction with doctor’s use of treatment agreement,  
  pill counts, questionnaires in pain management, 
  safety n = 1122; completer n = 558
724 (65) 277 (25) 414 (74) 115 (21)
Table 3 clinician global assessment at visit 5
n (%) Safety population 
n = 1487
Completer population 
n = 561
Very satisfied Satisfied Very satisfied Satisfied
Treating moderate-to-severe pain, 
safety n = 1343; completer n = 558
319 (24) 530 (40) 245 (44) 265 (48)
improvement in chronic pain, 
safety n = 1342; completer n = 558
304 (23) 536 (40) 235 (42) 269 (48)
Utility of risk assessment program, 
safety n = 1344; completer n = 558
366 (27) 644 (48) 231 (41) 254 (46)Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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musculoskeletal, osteoarthritic, and/or neuropathic pain, 
although the study protocol did not include a specific workup 
to establish a differential diagnosis. As in clinical practice, 
patients were allowed to continue taking other medications, 
unless they were primarily indicated for analgesia. Given that 
a substantial proportion of patients also had depression and/
or anxiety during the study, it is possible that some of the 
medications they were taking for these conditions functioned 
as adjunctive analgesics, impacting the results. While having 
the potential to impact the study results, this limitation might 
more closely represent the situation in a real-world population 
of patients on a variety of medications.
The current study is the first large-scale study to assess the 
utility of the universal precautions approach, including risk 
assessment and stratification, as well as the use of morphine 
sulfate extended-release in the primary care setting. Future 
studies can build upon the knowledge by including a means 
of identifying how investigators make treatment and risk 
assessment decisions using the available information, and 
how these decisions impact patient outcomes.
Conclusion
In this primary care population of patients with chronic, mod-
erate-to-severe pain, using a universal precautions approach 
to pain management and treatment with morphine sulfate 
extended-release, patients experienced decreased pain inten-
sity scores (average, least, and worst) and reduced pain inter-
ference with activities of daily living from   baseline   values. 
The most common adverse events were those commonly seen 
with opioid therapy, ie, constipation, nausea, vomiting, and 
somnolence. Most investigators and patients were satisfied 
or very satisfied with the use of morphine sulfate extended-
release for treatment of moderate-to-severe pain and the level 
of improvement in pain control attained with this therapy.
While pain relief was achieved in this study, the proportion 
of patients rated at moderate or greater risk for opioid misuse 
and abuse and the identification of illicit drug use suggest a 
need for continuous patient monitoring. Further education of 
primary care providers, and development of better strategies 
to aid in the identification of patients with chronic pain 
receiving long-term opioid therapy who may be at risk for 
drug misuse and abuse, may also be warranted.
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